2024-10-16 20:24:00
The advanced platform integrates powerful multi-agent AI orchestration that can accelerate AI productivity improvement in enterprises
Dozens of companies have already used the platform to quickly identify, build and test AI decision-making applications that can deliver great business value.
TEANECK, NJ, Oct. 16, 2024 /PRNewswire/ – Cognizant (NASDAQ:CTSH) today announced significant expansions to its Cognizant Neuro® AI platform designed to enable companies to quickly discover, prototype and develop AI use cases that can improve decision making, leading to better business performance and new revenue opportunities.
According to data from a study by Cognizant und Oxford Economics Most companies (76%) want to use AI to create new revenue streams, but are struggling to implement and scale cross-company use cases. Many (70%) also believe they are not progressing fast enough. Cognizant Neuro® AI extensions address these problems – in just minutes, executives can identify which business problems to address, isolate them, and generate synthetic data or import their own anonymized data to start building AI models. The platform can then predict and provide guidance for achieving business outcomes and justify these decisions, allowing companies to quickly assess the impact of a wide range of use cases.
The expanded Cognizant Neuro® AI platform is now available to Cognizant customers and has already been tested, proven and deployed by dozens of customers and is backed by multiple patents. It can be used for almost any industry or business challenge that requires data analysis, from inventory management and dynamic pricing to fraud prevention and efficient staffing. The Neuro® AI platform enhancements began as research projects in the Cognizant AI Research Lab Earlier this year brought into being. The lab focuses on the research and development of decision-based AI systems, and these improvements are the lab’s first developments to be integrated into a commercial offering.
Gilead Sciences, a leading biopharmaceutical company and Cognizant customer, commented on the enhanced Neuro® AI platform:
“Many organizations struggle to apply AI beyond predicting outcomes, and that’s because solving real business problems typically involves thousands of different scenarios with often conflicting priorities,” said Murali Vridhachalam, Head of Cloud, Data and Analytics at Gilead Sciences. “With these latest updates, Cognizant Neuro® AI is the only platform I’ve seen that enables companies to quickly implement end-to-end Gen AI use cases across applications and uncover tangible, revenue-driving opportunities . Its innovative multi-agent approach to managing decision-making processes sets it apart from others in the industry.”
Another Cognizant customer, Bayer Crop Science, also shared their experience with the expanded platform:
“Agriculture is one of the most demanding professions that requires complicated decisions taking into account environmental uncertainties and the need to balance social, economic and environmental goals,” said Patricio Salvatore La Rosa, Head of Decision Science at Bayer Crop Science. “ We have directly tested several fundamental components of Cognizant Neuro® AI, particularly LEAF, which has enabled us to effectively navigate complex scenarios by leveraging the collaborative capabilities of specialized AI agents, we look forward to solving complicated decision-making problems in a reliable way to approach it in a transparent and trustworthy manner.”
Cognizant has integrated powerful new capabilities as part of Cognizant Neuro® AI enhancements, including a multi-agent use case discovery tool called Opportunity Finder, as well as a suite of Large Language Model (LLM) wizards that provide powerful Form an AI decision machine. Customers first interact with the platform through the Opportunity Finder, an LLM assistant that helps them identify potential AI decision cases for their companies. The Model Orchestrator, with a drag-and-drop interface, then allows users to clean the data and apply a variety of machine learning models to it. Data preparation is streamlined through LLMs, and then machine learning models are applied to predict outcomes while evolutionary AI models dictate decisions. After training, the best models can be further queried via a web interface or queried via an LLM assistant.
The advanced Cognizant Neuro® AI platform is available with pre-built configurations that provide easy starting points for various use cases. These include healthcare (e.g. drug development and treatment plans), finance (e.g. cybersecurity and fraud prevention), agriculture (e.g. crop yield optimization and pesticide development), as well as general supply chain, call center, customer engagement templates and price optimization.
“Companies are struggling with how and where to use AI to solve business problems. “That’s why most AI use cases are limited to prediction-based outcomes or single LLM chat solutions,” said Babak Hodjat, Chief Technology Officer of AI at Cognizant. “Multi-agent AI systems are the key to solving these problems, which is why Cognizant Neuro® AI is now built with such a system at its core. This platform gives business decision makers – not just data scientists – the opportunity to use their own expertise to test and establish AI decision-making use cases in minutes and then provide the resulting model code for iterative scaling.
According to Gartner®, “multiple agents can work toward a common goal that goes beyond the capabilities of individual agents. The combined use of multiple agents can tackle complex tasks that individual agents cannot, while creating more adaptable, scalable and robust solutions.”1
Neil Ward-Dutton, VP Automation, AI and Analytics at IDC, also commented: “As companies now look to approach AI strategically and move beyond experimentation, they need to understand how to identify and prioritize use cases. Vendors that can leverage technology to accelerate use case identification and then use that technology to test and scale implementations will be in a strong position.”
To learn more about the advanced Cognizant Neuro® AI platform and sign up for a demo, visit cognizant.com/neuroai.
About Cognizant
Cognizant (Nasdaq: CTSH) develops modern businesses. We help our customers modernize technologies, redesign processes and transform experiences so they can stay at the forefront of our rapidly changing world. Together we improve everyday life. For more information, see www.cognizant.com or @cognizant.
About the Cognizant AI Research Lab
The mission of the Cognizant AI Research Lab is to maximize human potential with Decision AI. Decision AI is a form of AI that combines generative AI, multi-agent architecture, deep learning and evolutionary AI to create sophisticated decision systems. Decision AI is the foundation of Cognizant’s Neuro® AI platform, used by Fortune 500 companies and nonprofits to find new ways to exceed their goals. The platform enables companies to quickly develop AI that optimizes decision-making, leading to revenue growth and social progress.
Led by AI pioneers Babak Hodjat and Risto Miikkulainen, the lab works with institutions, universities and technology partners to responsibly develop groundbreaking AI solutions. With over 75 patents (granted or pending), the laboratory distinguishes itself by combining scientific innovation and commercial application. It supports Cognizant’s mission to improve everyday life and focuses on business and AI applications for good.
Forward-Looking Statements
This press release contains statements that may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks, uncertainties and assumptions regarding future events that may not prove to be accurate. These statements include, but are not limited to, express or implied forward-looking statements regarding the adoption of generative artificial intelligence and the impact of generative artificial intelligence on the workforce, businesses and the economy. These statements are neither promises nor guarantees, but are the results of the study mentioned above and are subject to a variety of risks and uncertainties, many of which are beyond our control and which could cause actual results to differ materially from those discussed in referred to in these forward-looking statements. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Factors that could cause results to differ materially from those expressed or implied include general economic conditions, the effects of technological developments and competition, the competitive and rapidly changing nature of the markets in which we compete, the competitive talent market and its impact on employee recruitment and retention, and the other factors discussed in our most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Cognizant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
1 Gartner: Innovation Insight: AI Agents, April 3, 2024. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the United States and internationally and is used herein with permission. All rights reserved.
For further information please contact:
USA Europe/APAC Indien Name Gabrielle Gugliocciello Christina Schneider Rashmi Vasisht E-Mail mailto:Gabrielle.Gugliocciello@ E-Mail mailto:christina.schneid E-Mail mailto:rashmi.vasi cognizant.com er@cognizant.com sht@cognizant.com
1729122847
#Cognizant #announces #multiagent #orchestration #Neuro #platform